Even for killer T cells, which are specialised immune cells, searching for and eliminating cancer cells around the clock can be challenging. Scientists can produce stronger cancer-killing cells if they understand why killer T cells become exhausted.
Two new genes have been discovered by Queen Mary University of London researchers that render people with head and neck cancer resistant to chemotherapy. Cancer cells that were previously resistant to chemotherapy can now respond to it by silencing one of these genes.
Researchers from Queen Mary University of London have identified two new genes that make patients with head and neck cancer resistant to chemotherapy. By suppressing one of these genes, cancer cells that were previously resistant to chemotherapy can now respond to it.
The therapy, tested in mouse models, combines a delivery system that targets cancer cells with a specially modified version of microRNA-34a, a molecule that acts “like the brakes on a car,” slowing or stopping cell division, said Andrea Kasinski, lead author and the William and Patty Miller
Researchers have conducted an in-depth examination of the proteins responsible for cancer across a variety of tumour types, providing knowledge that cannot be determined only by genome sequencing
Glioblastoma, the most prevalent and lethal type of brain cancer, spreads quickly, invading and destroying healthy brain tissue. The tumour shoots malignant tendrils into the brain, making surgical removal of the tumour extremely difficult or impossible.
The LINAC provides targeted laser-guided beam Radiotherapy, which specifically targets the cancer cells only and does not destroy the surrounding healthy tissue. This 360 degrees rotatory Radiotherapy machine can be used for treatment of any type for cancer.
Researchers have discovered a protein that is crucial to the operation of numerous novel cancer medicines. The discovery, according to the researchers, will probably help with efforts to optimize the use of immunotherapies against a number of difficult tumors.
In a ground-breaking development in the fight against myeloma, Israeli researchers developed a targeted procedure to effectively destroy cancer within the bone marrow.
A group of researchers led by Nanyang Technological University, Singapore (NTU Singapore) discovered that a cancer medicine that is currently on the market might be modified to target a subgroup of malignancies that are frequently linked with poor outcomes and lack focused therapy choices.
According to a recent Yale study, cancer cells with extra chromosomes depend on those chromosomes for tumour growth, and eliminating them prevents the cells from developing into tumours. The researchers' findings suggest that a unique strategy for treating cancer may involve selectively targ